Logo

American Heart Association

  30
  0


Final ID:

ANGPTL3 inhibitors for reduction of cardiovascular disease risk

  • Rosenson, Robert  ( MT SINAI SCHOOL MEDICINE , New York , New York , United States )
  • Author Disclosures:
    Robert Rosenson: DO have relevant financial relationships ; Research Funding (PI or named investigator):Amgen:Active (exists now) ; Consultant:Intercept Pharmaceuticals:Past (completed) ; Consultant:Eli Lilly:Active (exists now) ; Consultant:Editas Medicine:Past (completed) ; Consultant:CRISPER Therapeutics:Past (completed) ; Consultant:Arrowhead:Active (exists now) ; Consultant:Amgen:Active (exists now) ; Research Funding (PI or named investigator):Shanghai Argo Biopharmaceutical Co.:Active (exists now) ; Research Funding (PI or named investigator):89Bio:Active (exists now) ; Research Funding (PI or named investigator):Novo Nordisk:Past (completed) ; Research Funding (PI or named investigator):Novartis:Active (exists now) ; Research Funding (PI or named investigator):NIH:Active (exists now) ; Research Funding (PI or named investigator):Merck:Active (exists now) ; Research Funding (PI or named investigator):Eli Lilly:Active (exists now) ; Research Funding (PI or named investigator):Arrowhead:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Triglyceride-Rich Lipoproteins in Cardiovascular and Metabolic Disease

Friday, 11/07/2025 , 12:30PM - 01:45PM

Cardiovascular Seminar

More abstracts on this topic:
More abstracts from these authors:
Associations of Predicted CVD risk by the PREVENT Equation with AI-analyzed Coronary Atherosclerotic Plaque Characteristics

Gurevitz Chen, Fisher Rebecca, Muntner Paul, Fisher Edward, Rosenson Robert

Discussant

Lingvay Ildiko, Rosenson Robert

You have to be authorized to contact abstract author. Please, Login
Not Available